Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Jan;55(1):50-60.
doi: 10.1053/j.ajkd.2009.08.019. Epub 2009 Nov 22.

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group

Melanie S Joy  1 , Debbie S Gipson, Leslie Powell, Jacqueline MacHardy, J Charles Jennette, Suzanne Vento, Cynthia Pan, Virginia Savin, Allison Eddy, Agnes B Fogo, Jeffrey B Kopp, Daniel Cattran, Howard Trachtman
Affiliations
Clinical Trial

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group

Melanie S Joy et al. Am J Kidney Dis. 2010 Jan.

Abstract

Background: Patients with primary focal segmental glomerulosclerosis (FSGS) resistant to current treatment regimens are at high risk of progression to end-stage kidney disease. Antifibrotic agents, such as tumor necrosis factor alpha antagonists, are a promising strategy to slow or halt the decline in renal function, based on preclinical and clinical data.

Study design: Phase 1 clinical trial to assess the pharmacokinetics, tolerability, and safety of adalimumab, a human monoclonal antibody to tumor necrosis factor alpha.

Setting & participants: 10 patients (4 male and 6 female) aged 16.8 +/- 9.0 years with an estimated glomerular filtration rate of 105 +/- 50 mL/min/1.73 m(2) were studied.

Intervention: Adalimumab, 24 mg/m(2), every 14 days for 16 weeks (total, 9 doses).

Outcomes: Pharmacokinetic assessment, tolerability, and safety.

Measurements: Estimated glomerular filtration rate, proteinuria, and pharmacokinetic assessment after initial dosing and steady state.

Results: Pharmacokinetic evaluation indicated that the area under the curve was decreased by 54% (P < 0.001) and clearance was increased by 160% (P < 0.01) in patients with resistant FSGS compared with healthy controls and patients with rheumatoid arthritis. Adalimumab was well tolerated with no serious adverse events or infectious complications attributable to the drug. Proteinuria decreased by > or = 50% in 4 of 10 treated patients.

Limitations: Insufficient power to assess the safety or efficacy of adalimumab therapy for patients with resistant FSGS.

Conclusions: Pharmacokinetic assessment showed increased clearance of adalimumab in patients with resistant primary FSGS and validated the need to evaluate the disposition of novel therapies for this disease to define appropriate dosing regimens. The study provides a rationale to evaluate the efficacy of adalimumab as an antifibrotic agent for resistant FSGS in phase 2/3 clinical trials.

Trial registration: ClinicalTrials.gov NCT00814255.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram summarizing patient screening and enrollment in the FONT Phase I trial
Figure 2
Figure 2
Adalimumab concentration versus time curves after Single Dose. Note that the drug concentrations are provided as ng/mL to enhance the clarity of the graphs.
Figures 3a and 3b
Figures 3a and 3b
3a: Linear regression model of ranked T½ versus UP:C (urine protein-creatinine ratio) at steady state. Data were ranked so that they would follow a normal distribution. The model resulted in r = −0.8990 (95% Confidence Interval −0.9761 to −0.6207), r2 −0.6207, p<0.001. 3b: Linear regression model of ranked T½ versus ranked serum albumin at steady state. Data were ranked so that they would follow a normal distribution. The model resulted in r = 0.7586 (95% Confidence Interval 0.2467 to 0.9395), r2 0.5755, p=0.01
Figures 3a and 3b
Figures 3a and 3b
3a: Linear regression model of ranked T½ versus UP:C (urine protein-creatinine ratio) at steady state. Data were ranked so that they would follow a normal distribution. The model resulted in r = −0.8990 (95% Confidence Interval −0.9761 to −0.6207), r2 −0.6207, p<0.001. 3b: Linear regression model of ranked T½ versus ranked serum albumin at steady state. Data were ranked so that they would follow a normal distribution. The model resulted in r = 0.7586 (95% Confidence Interval 0.2467 to 0.9395), r2 0.5755, p=0.01
Figures 4a and 4b
Figures 4a and 4b
4a: Linear regression model of Cl/Fss versus UPCR (urine protein-creatinine ratio). The model resulted in r = 0.8465 (95% Confidence Interval −0.1615 to −0.0693), r2 0.7165, p=0.02. 4b: Linear regression model of lnAUCss versus UP:C (urine protein-creatinine ratio). The model resulted in r = 0.9446 (95% Confidence Interval 1.3 to 8.095), r2 0.8923, p=0.001
Figures 4a and 4b
Figures 4a and 4b
4a: Linear regression model of Cl/Fss versus UPCR (urine protein-creatinine ratio). The model resulted in r = 0.8465 (95% Confidence Interval −0.1615 to −0.0693), r2 0.7165, p=0.02. 4b: Linear regression model of lnAUCss versus UP:C (urine protein-creatinine ratio). The model resulted in r = 0.9446 (95% Confidence Interval 1.3 to 8.095), r2 0.8923, p=0.001
See this image and copyright information in PMC

References

    1. Lopez-Olivo MA, Kallen MA, Ortiz Z, Skidmore B, Suarez-Almazor ME. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: A systemic review. Arthritis Rheum. 2008;59:1625–1638. - PubMed
    1. Shah SB, Hanauer SB. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008;8:159–168. - PubMed
    1. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarasova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–821. - PubMed
    1. Felderman M. Many cytokines are very useful therapeutic targets in disease. J Clin Invest. 2008;118:3533–3536. - PMC - PubMed
    1. Li X, Magenheimer BS, Xia S, Johnson T, Wallace DP, Calvet JP, Li R. A tumor necrosis factor-α-mediated pathway promoting autosomal dominant polycystic kidney disease. Nature Med. 2008;14:863–868. - PMC - PubMed

Publication types

MeSH terms

Associated data